Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Single and Multiple Ascending Dose Escalation, and Food-Effect Study of the Safety, Tolerability and Pharmacokinetics of INT-210 Capsules in Healthy Adult Subjects

NCT07616791 is registered in ClinicalTrials.gov with Innatus Therapeutics (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT07616791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07616791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Single and Multiple Ascending Dose Escalation, and Food-Effect Study of the Safety, Tolerability and Pharmacokinetics of INT-210 Capsules in Healthy Adult Subjects
Lead sponsor
Innatus Therapeutics (Shanghai) Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
September 4, 2025
Completion date
January 6, 2026
Enrollment
86 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ibd (inflammatory bowel disease)